Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 2, 1997, Pages 225-229

  Lehmann, David F ^a   Hurteau, Tracy E ^b   Newman, Nancy ^b   Coyle, Thomas E ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; VALPROIC ACID;

ADULT; ARTICLE; BRAIN TUMOR; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBAMAZEPINE; COHORT STUDIES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 0030771369     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90071-0     Document Type: Article

References (24)

1. Rodriguez L, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989;64:2420-3.
2. Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 1990;40: 1743-6.
3. Coyle T, Baptista J, Winfield J, Clark K, Poiesz B, Kirshner J, et al. Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol 1990; 8:2014-8.
4. Coyle T, Bushunow P, Winfield J, Wright J, Graziano S. Hypersensitivity reactions to procarbazine with MOP chemotherapy for glioma. Cancer 1992;69:2532-40.
5. Cairncross G, MacDonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013-21.
6. Longo D, Young R, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-306.
7. Sinha BK. Cytochrome P-450 and peroxidase dependent activation of procarbazine and iproniazid in mammalian cells. Free Radic Res Commun 1991;15: 189-95.
8. Park BK, Kitteringham NR. Drug protein conjugation and its immunological consequences. Drug Metab Rev 1990;22:87-144.
9. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 1990;18:784-7.
10. Smith MC, Bleck TP. Convulsive disorders: toxicity of anticonvulsants. Clin Neuropharmacol 1991;14:97-115.
11. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-58.
12. Hobbs WR, Rail TW, Verdoorn TA. Hypnotics and sedatives: ethanol. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 1996:361-96.
13. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effects of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
14. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29:619-24.
15. Levin VA, Stearns J, Byrd A, Finn A, Weinkam RJ. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)- 1-nitrosourea (BCNU), 1(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther 1979;208:1-6.
16. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990;27:226-8.
17. Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992;10:311-5.
18. Mross K, Bewermeier P, Kruger W, Stockschlader M, Zander A, Hossfeld DK. Pharmacokinetics of undiluted or diluted high dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 1994;12:1468-74.
19. Fetell MR, Grossman SA, Fisher J, Erlanger B, Stockel J, Piantodosi S. Preirradiation paclitaxel in glioblastoma multiforme (GBM): efficacy, pharmacology and drug interactions [abstract]. Proc Am Soc Clin Oncol 1996;15:153a.
20. Chang S, Schold C, Spence A, Berger M, McAllister L, Mehta M, et al. Phase I/II study of paclitaxel chemotherapy for recurrent malignant glioma: preliminary report of North American Brain Tumor Consortium [abstract]. Proc Am Soc Clin Oncol 1996;15: 153a.
21. Tweedie DJ, Erikson IM, Prough RA. Metabolism of hydrazine anticancer agents. Pharmacol Ther 1987;34: 111-27.
22. Shen WW. Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five year update. Int J Psychiatry Med 1995;25:277-90.
23. Cribb AE, Spielberg SP, Griffin GP. N4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P450 2C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic cytochromes. Drug Metab Dispos 1995;23:406-14.
24. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;334:1583-90.